藤黄健骨片治疗膝骨关节炎疗效Meta分析

Meta-analysis on the Efficacy of Tenghuang Jiangu Tablets for the Treatment of Knee Osteoarthritis

目的 系统评价藤黄健骨片治疗膝骨关节炎的临床疗效和安全性,为临床用药提供循证参考。方法 计算机检索中国知识资源总库(CNKI)、中国学术期刊数据库(万方数据)、中文科技期刊数据库(VIP)、中国生物医学文献数据库(CBM)、PubMed、Cochrane Library、Embase建库至2022年7月29日藤黄健骨片单独服用或联合常规疗法治疗膝骨关节炎随机对照试验(RCT)。采用Cochrane系统评价员手册5.1.0进行文献质量评价,采用RevMan5.4进行Meta分析。结果 共纳入9项RCT,涉及1 029例患者。Meta分析结果显示:试验组总有效率[OR=4.26,95%CI(2.59,7.02),P<0.000 01]、VAS评分[MD=-1.32,95%CI(-2.31,-0.33),P<0.01]、WOMAC评分[MD=-12.98,95%CI(-24.65,-1.31),P<0.05]均优于对照组。单独服用藤黄健骨片试验组不良反应发生率低于对照组[OR=0.19, 95%CI(0.05,0.69),P<0.05]。结论 采用藤黄健骨片单用或者联合常规疗法治疗膝骨关节炎疗效确切,安全性好。但纳入研究质量偏低,尚需开展更多大样本、高质量的RCT验证。

Objective To systematically evaluate the clinical efficacy and safety of Tenghuang Jiangu Tablets in the treatment of knee osteoarthritis;To provide evidence-based reference for clinical medication.Methods RCTs about Tenghuang Jiangu Tablets alone or in combination with conventional therapy in the treatment of knee osteoarthritis were retrieved from CNKI,Wanfang Data,VIP,CBM,PubMed,Cochrane Library,and Embase from the establishment of the databases to July 29,2022.Cochrane system evaluator manual 5.1.0 was used for literature quality evaluation,and RevMan 5.4 was used for Meta-analysis.Results A total of 9 RCTs were included,involving 1029 patients.The Meta-analysis results showed that the overall effective rate of the experimental group[OR=4.26,95%CI(2.59,7.02),P<0.00001],VAS score[MD=-1.32,95%CI(-2.31,-0.33),P<0.01],and WOMAC score[MD=-12.98,95%CI(-24.65,-1.31),P<0.5]were better than the control group.The incidence of adverse reactions in the experimental group used Tenghuang Jiangu Tablets alone was lower than the control group[OR=0.19,95%CI(0.05,0.69),P<0.05].Conclusion Tenghuang Jiangu Tablets alone or in combination with conventional therapy is effective and safe in the treatment of knee osteoarthritis.However,the quality of the included studies is relatively low,and more large-scale and high-quality RCT validation is still needed.